Source-grounded facts extracted from cbdMD, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
cbdMD, Inc. amended Third Amendment to Lease (effective 2026-05-20).
“Effective May 20, 2026, cbdMD, Inc. (the “Company”) entered into a Third Amendment to Lease (the “Amendment”) to extend the Warehouse Lease entered into on August 27, 2019, as amended (the “Lease”)”
cbdMD, Inc. issued 425,000 shares of common stock to Gaia Botanicals, LLC.
“the Company acquired substantially all of Gaia’s assets, including Gaia’s brand name, online CBD marketplace, https://www.bluebirdbotanicals.com/ , related trademarks, inventory, certain other assets, and assumed certain liabilities.”
cbdMD, Inc. entered into Asset Purchase Agreement with Gaia Botanicals, LLC valued at 425,000 shares of the Company’s restricted common stock (effective 2026-01-12).
“On January 12, 2026 (the “Closing”), cbdMD, Inc., a North Carolina corporation (the “Company”) and Gaia Botanicals, LLC, a Colorado limited liability company (“Gaia”) and Gaia’s wholly owned subsidiaries entered into an Asset Purchase Agreement (the “Agreement”).”
cbdMD, Inc. issued 1,700,000 shares of Series B Convertible Preferred Stock of preferred stock to four institutional investors for aggregate gross proceeds of $1,700,000.
“the Investors were issued an aggregate of 1,700,000 shares of Series B Convertible Preferred Stock (“Series B Preferred Stock”) for aggregate gross proceeds of $1,700,000”
cbdMD, Inc.: The Company filed a Certificate of Amendment to the Certificate of Incorporation designating 1,700,000 shares of authorized preferred stock as Series B Convertible Preferred Stock (effective 2025-09-29).
“On September 29, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Designation”) designating 1,700,000 shares of the Company’s authorized preferred stock as Series B Convertible Preferred Stock, par value $0.001 per share.”
cbdMD, Inc.: Filed Articles of Amendment to the Articles of Incorporation to effect a one-for-8 reverse stock split, effective May 6, 2025 (effective 2025-05-06).
“effective May 6, 2025 and immediately following the Mandatory Exchange Date, the Company filed an Articles of Amendment to the Company’s Articles of Incorporation, as amended (the “Reverse Split Articles of Amendment”), which effected, at 4:02 p.m. Eastern Time on May 6, 2025, a one-for-8 reverse stock split of the Company’s issued and outstanding shares of Common Stock”
cbdMD, Inc.: Filed Articles of Amendment to the Certificate of Designation to automatically convert Series A Preferred Stock into Common Stock, effective May 6, 2025 (effective 2025-05-06).
“Effective May 6, 2025, the Company filed an Articles of Amendment to its the Certificate of Designation of Rights and Preferences 8.0% Series A Cumulative Convertible Preferred Stock (the “Automatic Preferred Conversion Articles of Amendment”) with the Secretary of State of the State of North Carolina effective 4:01 p.m. Eastern Time on May 6, 2025”
cbdMD, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).
“December 31, 2024, cbdMD, Inc. (the “Company”) received notification (the “Notice”) from the NYSE American LLC (the “NYSE American”) that the Company is no longer in compliance with an additional NYSE American continued”
cbdMD, Inc. shareholders approved Approval of issuance of shares upon conversion of convertible notes exceeding 19.9% of outstanding common stock at the 2024-03-29 meeting.
“Proposal 6: The approval of the issuance of shares of the Company’s common stock, representing more than 19.9% of our common stock outstanding upon the conversion of certain convertible notes issued by the Company pursuant to the Securities Purchase Agreement dated January 30, 2024 entered into by and between the Company and five institutional investors was approved, based upon the following final tabulation of votes: “For ” “Against ” “Abstain ” 906,703 14,362 4,849”
cbdMD, Inc. shareholders rejected Amendment to Certificate of Designation for Series A Preferred Stock to provide for automatic conversion into common stock at the 2024-03-29 meeting.
“Proposal 5: The approval of an amendment to the Certificate of Designation for the Series A to provide for the automatic conversion into common stock was not approved, based upon the following final tabulation of votes: Common Stock: “For ” “Against ” “Abstain ” 909,689 13,722 2,503 Series A: “For ” “Against ” “Abstain ” 1,790,169 1,674,962 -”
cbdMD, Inc. shareholders approved Advisory resolution on fiscal year 2024 compensation of named executive officers at the 2024-03-29 meeting.
“Proposal 4: The approval of an advisory resolution on the fiscal year 2024 compensation of the named executive officers was approved, based upon the following final tabulation of votes: “For ” “Against ” “Abstain ” 842,489 39,001 44,424”
cbdMD, Inc. shareholders approved Advisory vote on frequency of advisory vote on executive compensation at the 2024-03-29 meeting.
“Proposal 3: The approval of an advisory vote on the frequency of an advisory vote on executive compensation was approved, based upon the following final tabulation of votes: “One ” “Two ” “Three ” “Abstain ” 515,552 39,999 326,876 43,487”
cbdMD, Inc. shareholders approved Ratification of Cherry Bekaert LLP as independent registered public accounting firm at the 2024-03-29 meeting.
“Proposal 2: The appointment of Cherry Bekaert LLP as our independent registered public accounting firm and to audit our financial statements for the fiscal year ending September 30, 2024 was ratified, based upon the following final tabulation of votes: “For ” “Against ” “Abstain ” 1,048,934 2,071 2,904”
cbdMD, Inc. shareholders approved Election of Directors at the 2024-03-29 meeting.
“Proposal 1: The following directors were elected at the 2024 Annual Meeting of shareholders to hold office until the 2025 annual meeting of shareholders or their earlier resignation, removal or death: Directors “For ” “Against ” Bakari Sellers 894,360 31,554 William F. Raines, III 896,656 29,258 Scott G. Stephen 896,855 29,059 Dr. Sybil Swift 898,196 27,718”
Bradley Whitford was appointed as Chief Accounting Officer at cbdMD, Inc..
“Effective March 29, 2024, the Board of Directors (the "Board") of cbdMD, Inc. (the "Company") appointed Bradley Whitford, the Company's current Vice President of Finance, to serve as the Company's Chief Accounting Officer at the discretion of the Board.”
cbdMD, Inc. entered into License Agreement and Lease Forbearance Agreement with HSKL, Inc. valued at License grant and forbearance in exchange for $80,000 upfront and four monthly payments of $40,000 (effective 2024-03-14).
“Effective March 20, 2024 we entered into a License Agreement, dated as of March 14, 2024, by and between cbdMD, Inc. and HSKL, Inc. (the “License Agreement”) and Lease Forbearance Agreement, dated as of March 14, 2024, by and between cbdMD, Inc. and HSKL, Inc. (the “Forbearance Agreement”).”
cbdMD, Inc. entered into Securities Purchase Agreement with five institutional investors valued at $1,250,000 gross proceeds (effective 2024-02-01).
“Effective February 1, 2024 (the “Closing Date”), cbdMD, Inc. (the “Company”) entered into a Securities Purchase Agreement dated January 30, 2024 (the “Purchase Agreement”) with five institutional investors (the “Investors”) whereby the Investors advanced the Company an aggregate of $1,250,000 gross proceeds and the Company issued each Investor an Senior Secured Original Issue Discount Convertible Promissory Note, in the aggregate principal amount of $1,541,666 (the “Notes”).”
cbdMD, Inc. entered into Underwriting Agreement with Maxim Group LLC valued at $2.5 million (effective 2023-04-30).
“On April 30, 2023, cbdMD, Inc., a North Carolina corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC as representative of the underwriters named therein (the “Underwriter”) relating to the issuance and sale of 1,350,000 shares of the Company’s common stock, par value $0.001 per share (the “Offering”).”
cbdMD, Inc.: Filed Articles of Amendment to effect a 1-for-45 reverse stock split of common stock (effective 2023-04-24).
“On April 24, 2023, cbdMD, Inc. (the “Company”) filed an Articles of Amendment to the Company’s Articles of Incorporation, as amended, with the Secretary of State of the State of North Carolina (the “Articles of Amendment”), which effected, at 12:01 a.m. Eastern Time on April 24, 2023, a one-for-45 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).”
cbdMD, Inc. entered into Registration Rights Agreement with Keystone Capital Partners, LLC (effective 2023-03-02).
“Additionally, on March 2, 2023, the Company and Keystone entered into a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (“ SEC ”) covering the resale of shares of Common Stock that are issued to Keystone under the Purchase Agreement.”
cbdMD, Inc. entered into Purchase Agreement with Keystone Capital Partners, LLC (effective 2023-03-02).
“On March 2, 2023 cbdMD, Inc. (the “ Company ”) and Keystone Capital Partners, LLC (“ Keystone ”), entered into a common stock purchase agreement (the “ Purchase Agreement ”), which provides that subject to the terms and conditions set forth therein, the Company may sell to Keystone up to 12,687,012 shares of common stock, par value $0.001 per share, of the Company (the “ Common Stock ”), from time to time during the term of the Purchase Agreement.”
T. Ronan Kennedy departed as Interim Chief Executive Officer and Principal Executive Officer at cbdMD, Inc..
“On March 1, 2023, T. Ronan Kennedy agreed to serve as the Company’s Interim Chief Executive Officer and Principal Executive Officer and resigned as Chief Operating Officer of the Company in connection thereto.”
Kevin MacDermott resigned as Principal Executive Officer and President at cbdMD, Inc..
“On February 26, 2023, Kevin MacDermott notified cbdMD, Inc. (the “Company”) he was resigning as Principal Executive Officer and President of the Company, effective February26, 2023.”
cbdMD, Inc. shareholders approved Amendment to Articles of Incorporation to effect a reverse stock split at a ratio ranging from 1:20 to 1:50 at the 2023-02-16 meeting.
“Proposal 3: The amendment to our Articles of Incorporation, as amended, at the discretion of the board of directors, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-twenty (1:20) to one-for-fifty (1:50), at any time prior to the one-year anniversary date of the annual meeting, with the exact ratio to be determined by the board was approved, based upon the following final tabulation of votes: “For ” “Against ” “Abstain ” 26,518,758 3,437,896 6,057”
cbdMD, Inc. shareholders approved Ratification of Cherry Bekaert LLP as independent registered public accounting firm at the 2023-02-16 meeting.
“Proposal 2: The appointment of Cherry Bekaert LLP as our independent registered public accounting firm was ratified, based upon the following final tabulation of votes: “For ” “Against ” “Abstain ” 29,188,087 80,516 694,108”
cbdMD, Inc. shareholders approved Election of Directors at the 2023-02-16 meeting.
“Proposal 1: The following directors were elected at the 2023 annual meeting of shareholders to hold office until the 2024 annual meeting of shareholders or their earlier resignation, removal or death: Directors “For ” “Against ” Broker Non-Votes Bakari Sellers 26,273,192 3,119,747 569,772 William F. Raines, III 26,321,975 3,070,914 569,772 Scott G. Stephen 26,195,800 3,197,089 569,772 Dr. Sibyl Swift 26,887,466 2,505,473 569,772”
cbdMD, Inc. entered into Agreement for Advertising Placement with a360 Media, LLC valued at up to 6,060,606 shares of the Company’s common stock valued at $0.33 per share (effective 2023-02-01).
“On February 1, 2023, cbdMD, Inc. (the “Company”) entered into an Agreement for Advertising Placement (the “Agreement”) with a360 Media, LLC, a Delaware limited liability company (“a360”) in which a360 will provide professional media support and advertising placement in exchange for up to 6,060,606 shares of the Company’s common stock valued at $0.33 per share (the “Shares”).”
Martin A. Sumichrast resigned as Chief Executive Officer at cbdMD, Inc..
“whereby he resigned as the Company’s Chief Executive Officer, member of the Board of Directors, employee, and all other capacities from the Company, effective June 11, 2022.”
Martin A. Sumichrast resigned as Chief Executive Officer at cbdMD, Inc..
“On June 11, 2022, Mr. Martin A. Sumichrast entered into a Separation Agreement (the “Separation Agreement”) with cbdMD, Inc. (the “Company”) and its subsidiaries whereby he resigned as the Company’s Chief Executive Officer, member of the Board of Directors, employee, and all other capacities from the Company, effective June 11, 2022.”
Martin A. Sumichrast changed role as Chairman of the Board at cbdMD, Inc..
“Martin A. Sumichrast agreed to vacate the position of chairman of the board of directors on the Effective Date.”
Scott G. Stephen changed role as Chairman of the Board at cbdMD, Inc..
“On June 3, 2022 (the “Effective Date”) Scott G. Stephen, a member of the board of directors of cbdMD, Inc. (the “Company”) assumed the position of chairman of the board of directors of the Company as Martin A. Sumichrast agreed to vacate the position of chairman of the board of directors on the Effective Date.”
Kevin MacDermott was appointed as President at cbdMD, Inc..
“On the Effective Date, the Company entered into an Executive Employment Agreement with Kevin MacDermott pursuant to which Mr. MacDermott was hired to serve as the Company’s President.”
Sim Farar resigned as director at cbdMD, Inc..
“On January 5, 2022 Sim Farar announced his resignation from our board of directors, effective immediately.”
John J. Wiesehan resigned as Chief Revenue Officer at cbdMD, Inc..
“On December 1, 2021, John J. Wiesehan entered into a Separation and General Release (the “Separation Agreement”) with the cbdMD, Inc. (the “Company”) and its subsidiaries resigning as Chief Revenue Officer and all other capacities, effective December 1, 2021.”
John J. Wiesehan III was appointed as Chief Revenue Officer at cbdMD, Inc..
“Mr. John J. Wiesehan III was appointed Chief Revenue Officer of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.